← FDA DRUG APPROVALS

FDA ANDA · ANDA211180

HALOPERIDOL DECANOATE

Sponsor: ZYDUS PHARMS

APPLICATION
ANDA211180
TYPE
ANDA
ORIGINAL APPROVAL
2019-10-22
LATEST ACTION
2026-01-05
ROUTE
INTRAMUSCULAR, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

HALOPERIDOL DECANOATEPrescription
HALOPERIDOL DECANOATE EQ 50MG BASE/ML · INJECTABLE · INJECTION
HALOPERIDOL DECANOATEPrescription
HALOPERIDOL DECANOATE EQ 100MG BASE/ML · INJECTABLE · INJECTION

Approval history

2026-01-05Labeling · Supplement 5 · standardAP
2023-03-27Labeling · Supplement 3 · standardAP
2019-10-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →